Compare Nucor Corporation (NUE) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Revvity Inc — how do they compare? Nucor Corporation trades at $250.33 (market cap $55.84B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Nucor Corporation is far larger — about 3.3× Revvity Inc's market cap, and Nucor Corporation pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Revvity Inc for 12 Days on average.
| NUE | RVTY | |
|---|---|---|
Market Cap | $55.84B | $16.98B |
Volume | 848,835 | 1,456,900 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $157.36 |
52-Week Low | $131.78 | $82.26 |
Typical Hold Time | 78 Days | 12 Days |
Enterprise Value | $60.25B | $19.30B |
Dividend Yield | 0.91% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.14, down 0.12% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with a moderate buy analyst consensus and a $266.88 price target. Revenue rebounded to $32.49B in 2025, though net margins have compressed from 2022 peaks. Recent news highlights steel sector volatility and Nucor's Q3 2026 guidance projecting higher earnings on improved pricing.
Outlook remains cautiously optimistic with earnings growth potential from steel price strength and operational efficiency, balanced by competitive pressures from new capacity and cyclical demand risks. The stock offers value at a P/E of 19.64 and a solid dividend history, but investors face headwinds from margin pressure and industry competition.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
